Cargando…
SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398211/ https://www.ncbi.nlm.nih.gov/pubmed/36034738 http://dx.doi.org/10.1016/S2665-9913(22)00221-1 |
| _version_ | 1784772284685221888 |
|---|---|
| author | Boekel, Laura Besten, Yaëlle R Hooijberg, Femke Wartena, Rosa Steenhuis, Maurice Vogelzang, Erik Leeuw, Maureen Atiqi, Sadaf Tas, Sander W Lems, Willem F van Ham, S Marieke Eftimov, Filip Stalman, Eileen W Wieske, Luuk Kuijpers, Taco W Voskuyl, Alexandre E van Vollenhoven, Ronald F Gerritsen, Martijn Krieckaert, Charlotte Rispens, Theo Boers, Maarten Nurmohamed, Mike T Wolbink, Gertjan |
| author_facet | Boekel, Laura Besten, Yaëlle R Hooijberg, Femke Wartena, Rosa Steenhuis, Maurice Vogelzang, Erik Leeuw, Maureen Atiqi, Sadaf Tas, Sander W Lems, Willem F van Ham, S Marieke Eftimov, Filip Stalman, Eileen W Wieske, Luuk Kuijpers, Taco W Voskuyl, Alexandre E van Vollenhoven, Ronald F Gerritsen, Martijn Krieckaert, Charlotte Rispens, Theo Boers, Maarten Nurmohamed, Mike T Wolbink, Gertjan |
| author_sort | Boekel, Laura |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9398211 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93982112022-08-24 SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period Boekel, Laura Besten, Yaëlle R Hooijberg, Femke Wartena, Rosa Steenhuis, Maurice Vogelzang, Erik Leeuw, Maureen Atiqi, Sadaf Tas, Sander W Lems, Willem F van Ham, S Marieke Eftimov, Filip Stalman, Eileen W Wieske, Luuk Kuijpers, Taco W Voskuyl, Alexandre E van Vollenhoven, Ronald F Gerritsen, Martijn Krieckaert, Charlotte Rispens, Theo Boers, Maarten Nurmohamed, Mike T Wolbink, Gertjan Lancet Rheumatol Comment Elsevier Ltd. 2022-11 2022-08-23 /pmc/articles/PMC9398211/ /pubmed/36034738 http://dx.doi.org/10.1016/S2665-9913(22)00221-1 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Boekel, Laura Besten, Yaëlle R Hooijberg, Femke Wartena, Rosa Steenhuis, Maurice Vogelzang, Erik Leeuw, Maureen Atiqi, Sadaf Tas, Sander W Lems, Willem F van Ham, S Marieke Eftimov, Filip Stalman, Eileen W Wieske, Luuk Kuijpers, Taco W Voskuyl, Alexandre E van Vollenhoven, Ronald F Gerritsen, Martijn Krieckaert, Charlotte Rispens, Theo Boers, Maarten Nurmohamed, Mike T Wolbink, Gertjan SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period |
| title | SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period |
| title_full | SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period |
| title_fullStr | SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period |
| title_full_unstemmed | SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period |
| title_short | SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period |
| title_sort | sars-cov-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398211/ https://www.ncbi.nlm.nih.gov/pubmed/36034738 http://dx.doi.org/10.1016/S2665-9913(22)00221-1 |
| work_keys_str_mv | AT boekellaura sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT bestenyaeller sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT hooijbergfemke sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT wartenarosa sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT steenhuismaurice sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT vogelzangerik sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT leeuwmaureen sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT atiqisadaf sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT tassanderw sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT lemswillemf sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT vanhamsmarieke sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT eftimovfilip sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT stalmaneileenw sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT wieskeluuk sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT kuijperstacow sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT voskuylalexandree sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT vanvollenhovenronaldf sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT gerritsenmartijn sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT krieckaertcharlotte sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT rispenstheo sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT boersmaarten sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT nurmohamedmiket sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod AT wolbinkgertjan sarscov2breakthroughinfectionsinpatientswithimmunemediatedinflammatorydiseasesduringtheomicrondominantperiod |